Phase 1 Platinum Resistant Ovarian Cancer Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ovarian CancerEndometrial CancerOvarian Cancer Metastatic+4 more
Whitehawk Therapeutics, Inc.226 enrolled12 locationsNCT07444814
Recruiting
Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Endometrial CancerPlatinum Resistant Ovarian CancerPROC
Whitehawk Therapeutics, Inc.265 enrolled12 locationsNCT07470853
Recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Ovarian CancerPlatinum Resistant Ovarian CancerOvarian Cancer Recurrent
Outpace Bio, Inc.30 enrolled4 locationsNCT07030907